Mechanistically, the TME affects cancer cells through complex and dynamic pathways to modulate cancer-associated signaling, involving ligand-receptor interactions (e.g., PD-L1 binding of cancer cells to PD-1 of T cells), cytokines, metabolism reprogramming and KRAS pathways (31, 32). The gene discussed is KRAS; the disease is cancer.